As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The ULTRA Division of Hetero Healthcare focuses on providing therapeutic solutions across anti-infective care, pain management, and gastrointestinal health, addressing a range of acute and commonly encountered healthcare conditions.
Its portfolio encompasses therapies for bacterial infections, pain and inflammation, acidity and related gastrointestinal disorders, along with supportive care, enabling healthcare professionals to address diverse patient needs.
Backed by Hetero Healthcare’s commitment to quality, accessibility, and patient-centric care, ULTRA strives to provide dependable therapeutic solutions that support effective clinical management and better patient outcomes.
View by-
